



PCT/GB 2003 / 0 0 4 3 8 7



**PRIORITY  
DOCUMENT**

SUBMITTED OR TRANSMITTED IN  
COMPLIANCE WITH RULE 17.1(a) OR (b)

The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

REC'D 17 NOV 2003

WIPO


PCT

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed

*Stephen Hendley*

Dated

23 October 2003

## Patents Form 1/77

Patents Act 1977  
(Rule 16)THE PATENT OFFICE  
A  
Patent  
Office

11 OCT 2002

110CT02 E754844-1 0290  
P01/7700 0.00-02 70

1/77

## Request for grant of a patent

(See the notes on the back of this form. You can also get  
an explanatory leaflet from the Patent Office to help  
you fill in this form)

0223570.3 The Patent Office

Cardiff Road  
Newport  
Gwent NP9 1RH

1. Your reference 11038P1 GB/JM

2. Patent application number  
(The Patent Office will fill in this part)

0223570.3

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)Reckitt Benckiser (UK) Limited  
103-105 Bath Road  
Slough  
Berkshire  
SL1 3UH  
United Kingdom

Patents ADP number (if you know it)

07972136002

If the applicant is a corporate body, give the  
country/state of its incorporation

England

4. Title of the invention

Surface Treatment

5. Name of your agent (if you have one)

John C. McKnight

"Address for service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)Reckitt Benckiser plc  
Group Patents Department  
Dansom Lane  
Hull  
HU8 7DS  
United Kingdom

Patents ADP number (if you know it)

07799521001

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country

Priority application number  
(if you know it)Date of filing  
(day / month / year)7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier applicationNumber of earlier application  
(day / month / year)Date of filing  
(day / month / year)8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

Yes

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

# Patents Form 1/77

9. Enter the number of sheets for each of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	16
Claim(s)	3
Abstract	1
Drawing(s)	—

10. If you are also filing any of the following, state how many against each item.

Priority documents	
Translations of priority documents	
Statement of inventorship and right to grant of a patent (Patents Form 1/77)	
Request for preliminary examination and search (Patents Form 9/77)	One
Request for substantive examination (Patents Form 10/77)	One
Any other documents (please specify)	FS2

11. I/We request the grant of a patent on the basis of this application.

Signature

Date

*John C. McKnight*  
John C. McKnight

11 October 2002

12. Name and daytime telephone number of Person to contact in the United Kingdom

John C. McKnight (01482) 583719

## Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

## Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 1/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patents Office.

fPatents Form 1/77

0049562 11 OCT 02 09:42

DUPLICATE

1

## SURFACE TREATMENT

This invention relates to surface treatment compositions, and methods of treating surfaces. The invention relates particularly, but not exclusively, to compositions for treatment of the skin or hair to effect cleaning, and to related methods. For the purpose of this specification the term "cleaning" denotes removal of dirt (including grease) and/or combating of microorganisms.

10

Many compositions used for surface treatment include a surfactant or combination of surfactants which help to release dirt and/or microorganisms from the hard surface. Such compositions may also contain biocidal agents. Such compositions must be formulated carefully. For example surfactants may denature biocidal agents. Many biocidal agents have a detectable odour and the type and amount of a fragrance - typically an expensive ingredient - may need to be carefully selected. Foaming qualities are usually desired and these can be compromised by subtle aspects of the formulation selection. The viscosity of the compositions can be hard to control. The desired viscosity may be reduced as a function of time, temperature or pH. Optimal action of a biocidal agent in the composition may require a particular pH range, whereas a different pH range may be needed for optimal viscosity.

The nature and combination of surfactants chosen will also contribute significantly to the physical properties of such a formulation. Consideration of the solubilisation of biocidal agents in such systems is crucial, to obtain and maintain efficacy.

Frequently, a compromise is reached in known compositions in which either the viscosity or biocidal efficacy of the composition, or both, is sacrificed in part, in order to provide a composition which provides at least reasonable  
5 viscosity and biocidal activity. In many known compositions, the pH of the composition is raised or lowered in order to optimise the viscosity, or a combination of surfactants is utilised to promote thermodynamic instability, in order to increase efficacy.  
10 In some compositions where viscosity is not compromised, biocidal activity is less than optimal.

It would therefore be advantageous to provide a surface treatment composition which provides a surfactant and  
15 biocidal action at optimal viscosity for good handling and high surfactant efficacy, but without reducing the efficacy of any biocidal agent(s) in the composition. It would also be advantageous to provide a composition which can be stored for relatively long periods of time without  
20 significant detrimental alteration of viscosity of the composition, or significant reduction in either surfactant effect or biocidal activity. Furthermore, it would be desirable to provide a surface treatment composition which includes a surfactant, the composition being at the  
25 optimum pH for good viscosity and viscosity maintenance, and good surfactant and biocidal action.

It is therefore an aim of preferred embodiments of the invention to overcome the problems of the prior art.  
30

According to a first aspect of the present invention, there is provided a surface treatment composition comprising at least one surfactant and at least two

compounds selected from organic acids and salts of organic acids, and wherein the total concentration of the organic acids and salts of organic acids in the composition is at least 0.5% (w/v).

5

Preferred acids for use in the present invention are carboxylic acids. Preferred salts of organic acids for use with the present invention are carboxylates, preferably alkali metal carboxylates, more preferably potassium or, especially, sodium salts.

10

Preferred carboxylic acids/carboxylates are aliphatic; especially saturated aliphatic.

Other suitable organic acids and salts thereof may include benzene sulphonic acid and other aromatic sulphonic acids, uric acid and other purine-containing acids and ascorbic acid and other sugar-derived acids.

Suitably one of the organic acids or salt of an organic acid has two or more carboxylic acid or carboxylate groups.

In a preferred embodiment, one of said compounds is an organic acid or a salt of an organic acid, having two or more carboxylic acid or carboxylate groups, and another of said compounds is an organic acid or a salt of an organic acid, having one carboxylic acid or carboxylate group.

In another preferred embodiment, one of said compounds is an organic acid or a salt of an organic acid, having three carboxylic acid or carboxylate groups, and another of said

compounds is an organic acid or a salt of an organic acid, having one or two carboxylic acid or carboxylate groups.

Suitable organic acids/salts with one carboxylic acid or carboxylate group include linear or branched optionally substituted hydroxyalkyl carboxylic acids/salts or alkylmonocarboxylic acids/salts, of 1 to 8 chain carbon atoms, preferably 1 to 6 chain carbon atoms.

10 A suitable monocarboxylic acid/salt is formic, acetic, chloroacetic, dichloroacetic, benzoic, 2,4,6-trihydroxybenzoic, 2-aminobenzoic, pyruvic, quinolinic, 2-chlorobenzoic, glyoxylic, thioacetic, glyceric, acetoacetic, hippuric, glycolic acid, and especially, 15 lactic acid; or salts thereof.

Suitable organic acids/salts with two carboxylic acids or carboxylate groups include linear or branched optionally substituted hydroxyalkyldicarboxylic acids/salts or 20 alkylldicarboxylic acids/salts, of 2 to 10 chain carbon atoms, preferably 2 to 8 chain carbon atoms. Preferred organic dicarboxylic acids/salts include tartaric, oxalic, maleic, aspartic, L-glutamic, oxaloacetic, 2-oxoglutaric, malonic, phthalic, methylmalonic, mesaconic, 25 methylsuccinic, glutaric, malic and adipic acids or salts thereof.

Suitable organic acids/salts with three carboxylic acids or carboxylate groups include linear or branched 30 optionally substituted hydroxyalkyltricarboxylic acids/salts, alkyltricarboxylic acids/salts, of 3 to 10 chain carbon atoms, preferably 3 to 8 chain carbon atoms. Preferred organic tricarboxylic acids/salts include L-

argininosuccinic, isocitric and, especially, citric acid or salts thereof.

In a particularly preferred embodiment of the invention  
5 the composition comprises two organic acids and/or salts of organic acids; preferably carboxylic acids/salts. Preferably one of the organic acids/salts comprises lactic acid and/or lactate and another of the organic acids/salts comprises citric acid and/or citrate.

10

Preferably the composition comprises both a first organic acid and a salt of that organic acid.

Preferably the composition comprises both a second organic  
15 acid and a salt of that organic acid.

Suitably the total concentration of all of the organic acids and/or salts thereof in the composition is at least 1% (w/v), preferably at least 2% (w/v).

20

Suitably the total concentration of both organic acids and/or salts thereof in the composition is no more than 10% (w/v), preferably no more than 7.5% (w/v).

25 Suitably the pH of the composition is no more than 6, preferably no more than 5.5, more preferably no more than 5 and most preferably no more than 4.8.

Suitably the pH of the composition is at least 2,  
30 preferably at least 3 and more preferably at least 4.

One or, preferably, all of the organic acids and/or salts preferably act to buffer the composition to a desired pH.



The surfactant may be anionic, cationic, non-ionic, zwitterionic or amphoteric.

- 5 There may be more than one surfactant, preferably being independently selected from an anionic, cationic, non-ionic, zwitterionic or amphoteric surfactant.

Suitable non-ionic surfactants include alkoxy-  
10 alcohols, particularly alkoxy-ated fatty alcohols. These include ethoxylated and propoxylated fatty alcohols, as well as ethoxylated and propoxylated alkyl phenols, both having alkyl groups of from 7 to 16, more preferably 8 to 13 carbon chains in length.

15

Examples of alkoxy-ated alcohols include certain ethoxylated alcohol compositions presently commercially available from the Shell Oil Company (Houston, TX) under the general trade name NEODOL (trade mark), which are  
20 described as linear alcohol ethoxylates, certain compositions presently commercially available from the Union Carbide Company, (Danbury, CT) under the general trade name TERGITOL (trade mark) which are described as secondary alcohol ethoxylates, and contain compositions  
25 present commercially available from Clariant (UK) under the general trade name GENAPOL (trade mark) and which are described to be linear and branched alcohol ethoxylates.

Examples of alkoxy-ated alkyl phenols include certain  
30 compositions presently commercially available from the Rhône-Poulenc Company (Cranbury, NJ) under the general trade name IGEPAL (trade mark), which are described as octyl and nonyl phenols.

Suitable anionic surfactants include linear C<sub>8</sub> to C<sub>16</sub> alkyl sulphates, C<sub>8</sub> to C<sub>16</sub> alkylsulphonates, C<sub>8</sub> to C<sub>16</sub> alkylbenzenesulphonates, C<sub>8</sub> to C<sub>16</sub> alkyldiphenyloxide disulphonates and C<sub>4</sub> to C<sub>16</sub> alkylated naphthalene  
5 sulphonates. Suitable examples of anionic surfactants are sodium lauryl sulphonate and sodium dodecyl benzene sulphonate, or mixtures thereof. Preferably the anionic surfactant is selected from those comprising an alkali metal or ammonium cation.

10

A preferred composition of the present invention includes an anionic surfactant.

Suitable amphoteric surfactants include betaines.

15

A preferred composition of the present invention includes an amphoteric surfactant.

An especially preferred composition of the present  
20 invention includes an anionic surfactant in combination with an amphoteric surfactant. Preferably the ratio of the weight of the anionic surfactant to the weight of the amphoteric surfactant exceeds 1:1, and more preferably exceeds 2:1. Most preferably it exceeds 4:1. In highly  
25 preferred embodiments it exceeds 6:1.

Suitably the total concentration of the surfactant(s) in the composition is at least 2% (w/v), preferably at least 5% (w/v) and more preferably at least 8% (w/v).

30

Suitably the total concentration of the surfactant(s) in the composition is no more than 25% (w/v), preferably no more than 20% (w/v).

Suitably the composition is an aqueous composition. Preferably the composition comprises at least 50% (w/v) water, more preferably at least 60% (w/v), most preferably  
5 at least 70% (w/v).

The composition may comprise one or more further ingredients such as preservatives, thickeners, fragrance, chelating agents, and sodium chloride, for example.

10

The composition may contain a biocidal agent. The biocidal agent may be a bactericide, a viricide, a fungicide, a parasiticide, herbicide, algicide or any mixture of a combination thereof. Preferably it is a  
15 bactericide.

Suitably biocidal agents include phenolic compounds, such as PCMX.

20 There may be more than one biocidal agent present in the composition.

When a biocidal agent is present it may suitably be at a total concentration in the composition of at least 0.1%  
25 (w/v), preferably at least 0.2% (w/v) and more preferably at least 0.4% (w/v). Preferably it is present in an amount of up to 2% (w/v), more preferably up to 1% (w/v), most preferably up to 0.6% (w/v).

30 However it is believed that in preferred embodiments the acids and/or salts used in the invention may provide biocidal action, and it is possible that a traditional biocidal agent, such as an aromatic or heteroaromatic

compound, notably a phenolic compound (for example PCMX), may not be needed in some embodiments. Accordingly compositions not containing such a biocidal agent are within the scope of the present invention.

5

Preferred compositions of the present invention have a foaming action with water on the surface to be treated.

According to a second aspect of the present invention  
10 there is provided a surface treatment composition comprising at least one surfactant and at least two different organic buffers.

Suitably the organic buffers comprise organic acids and  
15 salts thereof, as described above. Of course the buffers are selected to be compatible with each other in the composition, and compatible with other components of the composition.

20 Suitably the or each surfactant is as described for the first aspect of the invention.

Suitably the composition further comprises a biocidal agent as described for the first aspect of the invention.

25

Other definitions given above in relation the first aspect are applicable to the second aspect.

The composition of the first or second aspect is  
30 preferably a liquid skin cleaner (for example a hand wash), a shower gel, or the like.

In accordance with a third aspect of the present invention there is provided a package containing a composition of the first or second aspect, the package comprising a container for the composition and a restricted dispenser outlet therefrom under the control of a user. The restricted dispenser outlet could be, for example, a spray nozzle of a pressurised canister, or the outlet of a pump-action container, for example a press-action "tap" or the spray nozzle of a trigger spray container.

According to a fourth aspect of the invention there is provided a method of treating a surface, the method comprising the step of contacting the surface with the surface treatment composition of the first or second aspects of the invention.

Suitably the surface is a surface of a person, in particular the skin or hair of a person.

The method may comprise coating the surface with the composition, directly from a container or via the agency of a separate part, for example a sponge, cloth or the hand, or spraying the surface with the composition.

The method may comprise the final step of rinsing the surface with an aqueous media, suitably clean water.

#### Example

The various aspects of the invention will now be described with reference to the following non-limiting examples in which the following materials are used:

PCMX - parachloro meta-xyleneol, supplied by Thomas Swan,  
Durham

5 EMPICOL ESB 70 (SLES) - sodium lauryl (C<sub>12-15</sub>) ethoxy (2-3  
EO) - sulphate surfactant, supplied by Huntsman

EMPIGEN BSFA - a betaine amphoteric surfactant, supplied  
by Huntsman

10 KATHON CG - a preservative; a mixture of thiazolinones,  
supplied by Rohn & Haas

JAGUAR EXCEL - a guar gum supplied by Rhodia

15 Pine fragrance

EMPICOL XPE/H - pearlisers, supplied by Huntsman

EMPICOL, EMPIGEN, KATHON and JAGUAR EXCEL are trade marks.

20

A composition of the invention was made up according to  
Formulation A given in Table 1 below, in which lactic  
acid/sodium lactate and citric acid/sodium citrate were  
used as two different buffering agents. A second  
25 formulation, Formulation B was also prepared in which the  
citric acid/sodium citrate was omitted. A control  
formulation, Formulation C was prepared in which no such  
organic acid or salt was present.

Table 1

Ingredient	Concentration (%w/v)		
	Formulation A	Formulation B	Formulation C
PCMX	0.5	0.5	0.5
EMPICOL ESB 70	9.0	9.0	9.0
EMPIGEN BSFA	1.5	1.5	1.5
Lactic acid	To pH 4.7	To pH 4.7	-
Sodium lactate	1.0	1.0	-
EMPICOL XPE/H	1.5	1.5	1.5
Fragrance	0.2	0.2	0.2
KATHON CG	0.02	0.02	0.02
Tetrasodium EDTA	0.3	0.3	0.3
Sodium citrate	0.7	-	-
Citric acid	To pH 4.7	-	-
JAGUAR EXCEL	0.3	0.3	0.3
Sodium chloride	-	-	Q.S
Deionised water	to 100%	to 100%	to 100%

5

The anti-microbial efficacy of Formulation A, Formulation B and Formulation C against *Staphylococcus aureus* (NCTC 10788) and *Escherichia coli* (NCTC 10418), was tested by performing a Handwash Efficacy Suspension Test.

10

The Handwash Efficacy Suspension Test is based on a standard test for the assessment of the rapid germicidal activity for antibacterial liquid and bar soap products, test preN12054 - chemical disinfection and antiseptics - Products for hygienic and surgical handrub and handwash, bactericidal activity, test method and requirements (phase 2, step 1); British Standard Institute draft for public

15

comment 95/561926 July 1995; but with use of a different *E. coli* strain).

The microbiocidal effect (ME) due to the action of the composition over the test contact time at the temperature at which the test was performed is expressed by the formula:

$$ME = \log N_C - \log N_D$$

10

where:

$N_C$  = Number of cfu/ml of the relevant control test (test mixture without composition).

15

$N_D$  = Number of cfu/ml of the test mixture after the action of the composition.

Results are graded as follows:

20

<u>ME values obtained</u>	<u>Activity</u>
>4.0	Excellent
3.0 - 4.0	Good
1.5 - 3.0	Moderate
0.5 - 1.5	Poor
<0.5	No activity

Formulations A, B and C were diluted in hard water to give a 50% v/v concentration, and were tested against *S.aureus* by contacting Formulations A, B and C with *S.aureus* cultures for one minute.

25



The tests were repeated a further two times to give a total of three repeats.

- 5 The results of the anti-microbial efficacy test against *S.aureus* are shown in Table 2.

Table 2

Formulation	Replicate ME Values			Median ME Value
	Run 1	Run 2	Run 3	
A	2.68	2.48	3.08	2.68
B	0.95	0.78	2.23	0.95
C	1.38	1.25	1.61	1.38

10

The anti-microbial efficacy of Formulations A, B and C was tested against *Escherichia coli*, using the Handwash Efficacy Suspension Test as detailed above. The results of the test against *E. coli* is shown in Table 3 below.

15

Table 3

Formulation	Replicate ME Values			Median ME Value
	Run 1	Run 2	Run 3	
A	4.68	4.95	4.57	4.68
B	2.24	2.60	2.60	2.60
C	0.24	0.09	0.17	0.17

- 20 The results of the test as shown in Tables 2 and 3 show that Formulation A exhibited moderate activity against *S.aureus* with a median ME value of 2.68.

Formulation A also showed good activity against *E. coli* achieving a median ME value of 4.68. Formulation B showed moderate activity against *E. coli* compared to Formulation A, with median ME value of 2.6, whereas Formulation C without organic buffers showed no activity against this organism.

Viscosity stability issues were also studied. The polymeric thickener CROTHIX was found to be unstable at the pH of Formulation B (pH 4.7). The pH of the formulation was increased to pH 5.2 to avoid viscosity degradation over time. The microbial efficacy of the product decreased considerably as compared to Formulation B at pH 4.7. Also, after storage at 50°C for two weeks, the pH 5.2 formulation exhibited significant viscosity degradation. It was noticed that pH decreased over this time period. As such, an increase in buffering capacity of Formulation B was investigated by increasing the amount of sodium lactate/lactic acid pairing, which resulted in excess of sodium ions, and as a result, the formulation was not capable of thickening.

Conversely, Formulation A, employing namely sodium citrate/citric acid and sodium lactate/lactic acid, counteracted the loss of thickening capacity at pH 5.2, such that Formulation A at pH 5.2 showed significantly decreased viscosity degradation over time, with no significant loss of biocidal effect, compared to Formulation B in which the pH was increased by 5.2 by addition of further sodium lactate/lactic acid.

The biocidal efficacy of Formulation A at pH 5.2 was much higher (5 log reductions v. *S.aureus* and *E. coli*) compared to Formulation B at pH 5.2.

- 5 In further tests of a corresponding composition containing the citric and lactic buffer pairs but not containing PCMX nor any other accepted biocidal agent, significant biocidal activity was still obtained.

## Claims

1. A surface treatment composition comprising at least one surfactant and at least two different organic acids and/or salts of organic acids, and wherein the total concentration of the organic acids and/or salts of organic acids in the composition is at least 0.5% (w/v).
2. A composition as claimed in Claim 1, wherein one of the organic acids or salt of an organic acid has two or more carboxylic acid or carboxylate groups.
3. A composition as claimed in Claim 1 or 2, wherein one of the organic acids or salts of an organic acid has two or more carboxylic acid or carboxylate groups, and another organic acid or salt of an organic acid has one carboxylic acid or carboxylate group.
4. A composition as claimed in any preceding claim, wherein one organic acid or salt has one carboxylic acid or carboxylate group, being a linear or branched optionally substituted hydroxyalkyl carboxylic acid or salt or alkylmonocarboxylic acid or salt comprising 1 to 8 chain carbon atoms.
5. A composition as claimed in any preceding claim, wherein an organic acid or salt with two carboxylic acid or carboxylate groups is a linear or branched optionally substituted hydroxyalkyldicarboxylic acid or salt or alkylldicarboxylic acid or salt, of 2 to 10 chain carbon atoms.

6. A composition as claimed in any preceding claim, wherein the organic acid or salt comprising three carboxylic acids or carboxylate groups is a linear or branched optionally substituted hydroxyalkyltri-carboxylic acid or salt or alkyltricarboxylic acid or salt, of 3 to 10 chain carbon atoms.
7. A composition as claimed in any preceding claim, wherein the composition comprises a first organic acid and a salt of that organic acid and a second organic acid and a salt of that organic acid.
8. A composition as claimed in Claim 7, wherein at least one of the organic acids and salts thereof acts to buffer the composition to a desired pH.
9. A composition as claimed in Claim 7 or 8, wherein the composition comprises lactic acid and/or lactate and citric acid and/or citrate.
10. A composition as claimed in any preceding claim, wherein the total concentration of all of the organic acids and/or salts thereof in the composition is at least 1% (w/v).
11. A composition as claimed in any preceding claim, wherein the pH of the composition is no more than 6.
12. A composition as claimed in any preceding claim, wherein the total concentration of surfactant(s) in the composition is at least 2% (w/v).

13. A composition as claimed in any preceding claim,  
wherein the composition further comprises a biocidal  
agent.
- 5 14. A surface treatment composition comprising at least  
one surfactant and at least two different organic  
buffers.
- 10 15. A composition as claimed in Claim 14, wherein the  
organic acids and salts thereof are as claimed in any  
one of Claims 2 to 7.
- 15 16. A package containing a composition as claimed in any  
preceding claim, the package comprising a container  
for the composition and a restricted dispenser outlet  
under the control of a user.
- 20 17. A method of treating a surface, the method comprising  
the step of contacting the surface with the surface  
treatment composition as claimed in any of claims 1 to  
15.
- 25 18. A method as claimed in Claim 17, wherein the method is  
a method of removing dirt and of removing or  
inhibiting microbial growth from skin or hair.
19. A composition, package or method substantially as  
described herein.

## ABSTRACT

5

## SURFACE TREATMENT

This invention describes a surface treatment composition, preferably for personal use, comprising at least one surfactant and at least two different organic acids and/or salts or organic acids, and wherein the total concentration of the organic acids and/or salts in the composition is at least 0.5% (w/v). The invention further extends to a method of treating a surface, preferably hair or skin, to remove dirt and to remove or inhibit microbial growth.

THE PATENT OFFICE  
23 OCT 2003  
Received in Patents  
International Unit

PCT Application

**GB0304381**





**This Page is Inserted by IFW Indexing and Scanning  
Operations and is not part of the Official Record**

**BEST AVAILABLE IMAGES**

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☐ **BLACK BORDERS**
- ☐ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- ☐ **FADED TEXT OR DRAWING**
- ☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- ☐ **SKEWED/SLANTED IMAGES**
- ☐ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- ☐ **GRAY SCALE DOCUMENTS**
- ☒ **LINES OR MARKS ON ORIGINAL DOCUMENT**
- ☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- ☐ **OTHER:** \_\_\_\_\_

**IMAGES ARE BEST AVAILABLE COPY.**

**As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.**